CHFW SEC filings, in plain English
Everything Consonance-HFW Acquisition Corp. has filed with the SEC that we hold — 40 filings, newest first, 3 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: Surrozen (SRZN), the de-SPAC successor to Consonance-HFW Acquisition Corp., reported Q2 2026 results: $102.0M cash, $5.0M Boehringer Ingelheim milestone revenue, and a $50.2M net income driven by $59.6M in non-cash gains on tranche and warrant liabilities. The company plans to submit an IND for SZN-8141 in DME by end of Q3 2026 and initiate the DUET Phase 1b/2a trial by year-end 2026. Why it matters: The filing confirms the post-merger company is executing on its clinical pipeline with defined near-term catalysts (IND and Phase 1b/2a initiation) while maintaining a $102M cash position. However, the balance sheet carries $196.3M in tranche liability and $124.7M in warrant liabilities, and the reported net income is entirely non-cash, driven by fair-value mark-to-market on these instruments.
What changed: Surrozen (formerly CHFW) filed its Q2 2026 10-Q showing $102.0M cash as of June 30, 2026, an accumulated deficit of $604.6M, and a net loss of $77.3M for the six months ended June 30, 2026. The company recognized $10.0M in collaboration revenue from Boehringer Ingelheim milestones, though BI is disputing $5.0M of the June 2026 milestone payment, claiming contractual grounds to reduce future payments. Why it matters: The SPAC merger is closed and the entity is now operating as Surrozen; the 2021 Public Warrants expire August 10, 2026, and the second tranche of the 2025 PIPE (~$95.1M gross) is contingent on FDA IND clearance for SZN-8141 by October 31, 2026. The Boehringer Ingelheim contractual dispute over milestone payments introduces revenue uncertainty, and the $196.3M tranche liability plus $124.7M in warrant liabilities create significant balance sheet volatility.
mandate languagenothing moved · 1 with no prior record of ours
- Mandate language
- we intend to focus our efforts on specific research and deve… · unchanged
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
mandate languagenothing moved · 1 with no prior record of ours
- Mandate language
- we intend to focus our efforts on specific research and deve… · unchanged
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Surrozen, Inc., the successor to Consonance-HFW Acquisition Corp., called its 2026 annual meeting for Wednesday, May 13, 2026 at 10:00 a.m. Pacific Time as a completely virtual meeting, record date March 18, 2026, at which there were 11,486,707 shares of common stock issued and outstanding, each with one vote. Items include electing Class II directors, among them David J. Woodhouse, Ph.D., to terms expiring in 2029 and ratifying Ernst & Young LLP for the year ending December 31, 2026. Why it matters: A float of 11,486,707 shares is very small, which makes both the stock illiquid and every equity issuance heavily dilutive in percentage terms. The inducement plan under Rule 5635(c)(4) is the mechanism to watch: it lets the company grant shares to new hires without shareholder approval, sitting outside the plan reserve holders do vote on. No trust or redemption right survives from the Consonance-HFW SPAC.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.